American Journal of Hematology
Fecha de publicación: 17 may 2018
Autores: Sara Ekberg, Mats Jerkeman, Per‐Ola Andersson, Gunilla Enblad, Björn E Wahlin, Sverker Hasselblom, Therese M. Andersson, Sandra Eloranta, Karin E. Smedby
Background: Survival has improved among patients with diffuse large B‐cell lymphoma (DLBCL) with the addition of anti‐CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population‐based level. Patients diagnosed with DLBCL 2000‐2013 (N = 7114) were identified through the Swedish Lymphoma Registry and classified according to the age‐adjusted International Prognostic Index (aaIPI).